Second 50 Financial

Physical AI

Five public companies betting that intelligence moves off the screen and into the world.

SERV · PRCT · RR
STXS · PDYN

A Thematic Small-Cap Basket

One Theme, Five Risks

Five bets on the robot economy.

These five share a story — AI leaving the screen and entering machines that move through the world — but they do not share a business. Prostate surgery, cardiac ablation, sidewalk delivery, restaurant service, and defense-drone autonomy have almost nothing in common at the operating level. Treat this as a thematic basket, not a diversified position: a bet that the robotics narrative keeps re-rating small caps, plus a handful of company-specific catalysts. Ranked below from most real to most speculative.

PROCEPT

Tier 1 · Quality

PRCT · Surgical Robotics

Aquablation robotic surgery for enlarged prostate. A real, scaling device business with recurring “razor & blade” revenue. The only name here that stands on fundamentals.

Price~$26.30

·

Market Cap~$1.5B

·

Price / Sales~4×

Stereotaxis

Tier 1 · Catalyst

STXS · Cardiac Robotics

Robotic magnetic navigation for heart-rhythm ablation. A real company at an inflection — its own MAGiC catheter just won FDA approval — but thinly capitalized and back-half-dependent.

Price~$1.93

·

Market Cap~$188M

·

Price / Sales~5× fwd

Serve Robotics

Tier 2 · Story

SERV · Delivery Robots

Autonomous sidewalk delivery, Uber- and Nvidia-backed. Fastest grower in the group off a tiny base — and burns roughly six times what it earns. A venture-stage bet on a public exchange.

Price~$8.88

·

Market Cap~$677M

·

Price / Sales~26× fwd

Palladyne AI

Tier 3 · Option

PDYN · Robot Autonomy Software

AI software that makes third-party drones and robots autonomous; defense-leveraged. Revenue is now real but acquisition-built. Highest beta in the group — a call option on the autonomy thesis.

Price~$7.23

·

Market Cap~$334M

·

Price / Sales~48×

Richtech

Tier 3 · Most Spec.

RR · Service Robots

Restaurant and hospitality robots plus a humanoid demo. Barely a business (~$5M revenue) but sitting on ~$329M of cash. Valued on narrative, diluting ~90% a year. Lottery-tier.

Price~$3.17

·

Market Cap~$644M

·

Price / Sales~125×

IMPORTANT · Prices and market caps are approximate snapshots as of late May 2026 and must be re-confirmed live before any action. Price/Sales uses trailing or forward revenue as noted. This is research, not a recommendation to buy. Five of these are speculative small- or micro-caps; suitability is addressed on the final page.

Tier 1 · Surgical Robotics

The only real business in the basket.

PROCEPT makes robotic systems that deliver Aquablation — a heat-free, image-guided waterjet that removes prostate tissue to treat enlarged prostate (BPH), a condition common in men over 50. Classic razor-and-blade: sell the ~$485K system, then earn a single-use handpiece (~$3,500) on every procedure.

$83.1M

Q1 Revenue · +20%

65%

Gross Margin

765

US Systems · +40%

$249M

Cash

The Bull Case

◊A growing installed base compounds recurring handpiece revenue — the durable part of the model.

◊The big optionality is the WATER IV trial taking Aquablation into localized prostate cancer — a far larger market, with FDA Breakthrough status.

◊Guides to its first positive adjusted EBITDA in Q4 2026; ~30% revenue grower with a European guideline tailwind.

The Bear Case

◊Stock has roughly halved over the past year after a Q4 miss and guidance cut — momentum is broken.

◊Still unprofitable on a GAAP basis; capital-equipment sales are lumpy and hospital-budget-sensitive.

◊Cheaper office-based rivals (UroLift, Rezum); the prostate-cancer payoff is years out and not guaranteed.

Verdict

The highest-quality name here and the only one suitable as a genuine equity holding. The de-rate has made the valuation (~4× sales) more defensible. The anchor of any robotics sleeve — with the prostate-cancer trial as the upside lever to watch.

Tier 1 · Cardiac Robotics

A real company at its make-or-break moment.

Stereotaxis steers catheters through the heart magnetically during ablation for heart-rhythm disorders. Razor-and-blade again: capital systems plus recurring disposables and service. Historically it depended on a partner’s catheters — and that is exactly what just changed.

$6.3M

Q1 Revenue · −16%

>$40M

FY26 Guide

$14.6M

Cash · No Debt

Jan ’26

MAGiC FDA Nod

The Bull Case

◊The make-or-break catalyst already landed: its own MAGiC catheter won FDA approval in Jan 2026 — moving high-margin disposable revenue in-house.

◊Stacked catalysts: Synchrony cockpit cleared, lower-cost GenesisX system, China approval, and the Robocath acquisition.

◊If the back-half ramp hits (>$40M FY), the multiple compresses fast from here.

The Bear Case

◊Long history of never making money; revenue is currently declining through the catheter transition.

◊Only ~$14.6M cash against a back-half-loaded guide — a dilutive raise near the lows is a live risk if MAGiC ramps slowly.

◊Competes with EP giants; the industry’s hot pulsed-field-ablation wave is not a Stereotaxis product.

Verdict

A real company at a real inflection — but financially fragile. This is a catalyst trade on MAGiC execution more than a buy-and-hold. Size it small; the next few quarters resolve into either a re-rate or a dilutive raise.

Tier 2 · Delivery Robots

Triple-digit growth. Six-times the burn.

Serve runs autonomous sidewalk delivery robots, spun out of Uber and backed by Uber and Nvidia, mostly through Uber Eats. In January 2026 it bought Diligent Robotics (Moxi hospital robots), pushing into higher-margin healthcare delivery.

$3.0M

Q1 Revenue · +578%

$26M

FY26 Rev Guide

$197M

Liquidity

~2,000

Robots Deployed

The Bull Case

◊Fastest top-line grower in the basket and the cleanest “physical AI in daily life” story.

◊Strategy shifting from “more robots” to revenue per robot; the Moxi/healthcare angle adds recurring revenue.

◊Analysts bullish (targets well above price); heavy short interest plus retail appeal create squeeze potential.

The Bear Case

◊Plans to spend ~6× what it earns ($160–170M opex on ~$26M revenue); unit economics unproven.

◊Near-certain future dilution — a serial issuer with ~4–5 quarters of runway.

◊~29% short interest cuts both ways; ~26× forward sales is detached from fundamentals.

Verdict

A venture-stage bet trading on a public exchange. Appropriate only as a small, speculative position you are willing to see cut in half. Watch the ramp toward the $26M revenue target and the next capital raise.

Tier 3 · Robot Autonomy Software

A software call option on autonomous machines.

Formerly Sarcos, Palladyne pivoted from robot hardware to autonomy software that makes third-party drones and robots intelligent — heavily defense- and drone-focused, with a notable Red Cat partnership on multi-drone flight.

$3.5M

Q1 Revenue · +107%

$24–27M

FY26 Guide

$43.7M

Cash

~$17M

Backlog

The Bull Case

◊Hardware-agnostic autonomy software is the highest-leverage layer of the robotics stack — if it works, it scales without building robots.

◊Defense and drone autonomy is a well-funded, tailwinded market.

◊Backlog and contract wins give it more substance than a pure story stock.

The Bear Case

◊~48× trailing sales — pricing in success not yet proven as recurring revenue.

◊Growth is acquisition-built, raising integration and dilution risk (active shelf + earnout overhang).

◊Deep losses, momentum-driven, thin coverage, and recent analyst downgrades.

Verdict

A speculative call option on defense-AI autonomy — the smallest, highest-beta position. It becomes “investable” only if those bookings convert to repeatable software revenue. Watch contract conversion against the $24–27M guide.

Tier 3 · Service Robots · Most Speculative

Mostly cash, barely a business.

Richtech makes service and hospitality robots — delivery bots, a robotic barista/bartender (ADAM), and a humanoid (Dex) — sold outright and via subscription. High-profile demos keep the story lively; the financials tell a harder truth.

$1.15M

Q1 Revenue · −9%

~$329M

Cash & Investments

~125×

Price / Sales

~90%

YoY Dilution

The Bull Case

◊The balance sheet: ~$329M cash is roughly half the market cap, so near-term failure risk is low.

◊High-visibility demos (Nvidia GTC, a Microsoft Azure collaboration, a humanoid debut) keep the narrative alive.

◊Optionality if any one of barista, delivery, or humanoid lines finds genuine product-market fit.

The Bear Case

◊~$5M annual revenue valued at ~125× sales (~60× even after netting cash); revenue is shrinking.

◊~90% annual dilution is the base case, not a tail risk; dual-class structure limits public holders.

◊Micro-cap, ~29% short interest, announcement-driven swings — demos running far ahead of signed revenue.

Verdict

The most speculative name here. The cash cushion means it will not die quickly, but ~125× sales with shrinking revenue and relentless dilution is not an investment on fundamentals. Treat strictly as lottery-tier money.

Suitability · The Second 50 Lens

Speculative by design. Size it like it.

Second 50 serves clients in or near retirement. State it plainly: these are speculative small- and micro-caps, unsuitable as core retirement holdings, they pay no income, and they should be expected to swing 50%+ peak-to-trough. Four of the five fund themselves by issuing stock, so ongoing dilution is the base case.

1

Cap the whole theme at low-single-digit % of the portfolio.

Money the client can lose in full without altering the retirement plan. The robotics sleeve is a satellite, never a core.

2

Anchor in PRCT; treat the rest as small, equal tickets.

PROCEPT is the one real business. STXS is a catalyst trade. SERV, PDYN, and RR are lottery-tier — size them as money you can lose entirely.

3

Horizon five to seven years, volatility spelled out in writing.

No dividends, ongoing dilution, and hype-cycle resets of 30–50%+ are normal for this cohort. Set the expectation before, not after.

4

For clients already drawing income, this cohort is generally inappropriate.

No income plus high sequence-of-returns risk make it a poor fit. Better suited to the younger end of the second 50.

Bottom Line

As a basket, this is a momentum bet on the robotics narrative, not a diversified position. For an RIA serving retirees it belongs only in a small, clearly-labeled speculative sleeve, anchored in PRCT — sized as money the client can afford to lose entirely.

Disclosures & Method

The fine print, plainly stated.

Research, not advice · This brief is prepared for Second 50 Financial’s internal and advisory use. It is for informational and educational purposes only. It is not personalized investment advice, not a solicitation, and not a recommendation to buy or sell any security. Any investment decision should consider the individual client’s objectives, risk tolerance, time horizon, and full financial picture, and should be made in the context of a suitability review.

Speculative securities · Five of the six issuers discussed are speculative small- or micro-capitalization companies. They are typically unprofitable, fund operations through ongoing equity issuance (dilution), pay no dividends, and can be highly volatile and illiquid. Drawdowns of 50% or more should be expected. An investment in any of these names can result in the loss of the entire amount invested.

Data & forward-looking statements · Prices, market capitalizations, and valuation multiples are approximate snapshots as of late May 2026 and must be independently re-confirmed before any action. Financial figures are drawn from company filings, earnings releases, and third-party aggregators believed reliable but not guaranteed. Company guidance, analyst price targets, trial outcomes, regulatory timelines, and catalysts are forward-looking and are not forecasts, representations, or guarantees of future results. Actual outcomes may differ materially.

Past performance and analyst targets do not predict future results. References to specific companies are illustrative and do not constitute a recommendation. Second 50 Financial is a fee-only, SEC-registered investment adviser; registration does not imply a particular level of skill or training. Verify all data independently before acting. This document may be superseded by subsequent research.